Novartis 3Q Profit Drops Slightly; Sales Down on Pressure on Generics
Novartis 3Q Profit Drops Slightly; Sales Down on Pressure on Generics
Filed under: drug treatment news 2011
Novartis kept its 2012 full-year outlook unchanged for net sales in line with 2011 and core operating income margin in constant currencies to be slightly below 2011. "While net sales were … Novartis's second-biggest selling drug, Gleevec–used to …
Read more on Fox Business
Celgene Drug Improves PFS in Phase III Melanoma Study
Filed under: drug treatment news 2011
Celgene separately today reported its results for the third quarter of 2012, which included global Abraxane sales of $ 106 million, down 6% on the same period in 2011. U.S. sales of Abraxane, at $ 81 million, were down 14%. International of the drug were …
Read more on Genetic Engineering News
Woman battles exercise addiction for nearly 20 years
Filed under: drug treatment news 2011
David J. Linden, a neuroscientist at Johns Hopkins University medical school, told the New York Times in October 2011 that exercise addicts can also feel tolerance, cravings and withdrawal. There are three types of addiction – chemical, process and …
Read more on Fox News
More drug treatment news 2011 Resources
INVESTMENT PHILOSOPHY
Our final sentiment towards equities was slightly declining as a result of market erosion from generics; this continues to hurt pharmaceutical profits. Cypher Sales eroded by cheaper Boston Scientific stent. Net profit in This puts pressure on overall profit margins and, as a result, current P/E … Access Doc